CN  /  EN




10 most-anticipated drug launches of 2020 by FiercePharma

  • 分类:最新消息
  • 作者:华讯知识产权
  • 来源:
  • 发布时间:2020-02-21 17:35
  • 访问量:

【概要描述】It'sFebruary of2020,whichmeansanotherroundofnewdruglaunchesisalreadyhittingtheroad.ThankstotheteamatEvaluatePharma,FiercePharma has assembledalistofthetop10most-anticipatednewdruglaunchesof2020basedon

10 most-anticipated drug launches of 2020 by FiercePharma

【概要描述】It'sFebruary of2020,whichmeansanotherroundofnewdruglaunchesisalreadyhittingtheroad.ThankstotheteamatEvaluatePharma,FiercePharma has assembledalistofthetop10most-anticipatednewdruglaunchesof2020basedon

  • 分类:最新消息
  • 作者:华讯知识产权
  • 来源:
  • 发布时间:2020-02-21 17:35
  • 访问量:

It's February of 2020, which means another round of new drug launches is already hitting the road. Thanks to the team at EvaluatePharma, FiercePharma has assembled a list of the top 10 most-anticipated new drug launches of 2020 based on estimated global sales in 2024.

1. Drug: Enhertu (fam-trastuzumab deruxtecan-nxki)

Companies: AstraZeneca, Daiichi Sankyo

Used for: HER2-positive breast cancer

Est. 2024 sales: $2.4 billion

The FDA approved antibody drug conjugate Enhertu in the final days of 2019 as a treatment for patients with inoperable or metastatic HER2-positive breast cancer who have already failed on at least two other treatments in the metastatic setting.  Enhertu will come with a boxed label warning for interstitial lung disease and embryo-fetal toxicity.  AstraZeneca and Daiichi will jointly develop and sell the drug outside of Japan, where Daiichi holds exclusive rights.

Enhertu is made up of Roche's Herceptin HER2-targeted antibody and a topoisomerase I inhibitor payload and is being tested in gastric cancer as well as in non-small cell lung and colorectal cancer.

The FDA based its approval on the phase 2 Destiny study, where Enhertu shrank tumors in 61% of patients and eliminated them completely in 6%, Daiichi said. A 97% disease control rate included patients who saw some tumor shrinkage but not enough to be considered responders. Nearly all of the Destiny patients (99%) experienced side effects, including nausea, vomiting and low white blood cell counts. Fifteen percent stopped treatment because of side effects, the company said.

2. Drug: ozanimod

Company: Bristol-Myers Squibb

Used for: multiple sclerosis

Est. 2024 sales: $1.598 billion

Ozanimod was a key component of Bristol-Myers Squibb’s $74 billion acquisition of Celgene. Ozanimod is an S1P receptor modulator, designed to dampen inflammatory activity by preventing immune cells from exiting the lymph nodes into the central nervous system. Multiple existing blockbusters and blockbuster hopefuls are targeting the same mechanism.

But to break the blockbuster barrier at all, it’ll have to compete with several FDA-approved drugs, as well as promising experimental drugs.  These include Novartis’ $3.3-billion-sales-per-year Gilenya, which is entangled in a patent fight and could face generics sooner than originally expected.  Celgene had touted ozanimod’s better safety profile than the older Novartis medication, particularly with regard to liver toxicities and heart side effects. But the MS up-and-comer has other, newer therapies to worry about.

On top of MS, Bristol-Myers is also gunning for ozanimod’s use in inflammatory bowel disease, where it’s in phase 3 testing.

3. Drug: inclisiran

Company: Novartis

Used for: high LDL cholesterol

Est. 2024 sales: $1.529 billion

Existing PCSK9 drugs—Amgen’s Repatha and Sanofi and Regeneron’s Praluent—have largely disappointed in sales, the current annualized sales for the two marketed drugs combined are just $1 billion. However, Novartis thinks it can do it differently with inclisiran, the centerpiece of its much-discussed $9.7 billion acquisition of The Medicines Company.

Inclisiran has put up comparable data on its ability to lower bad cholesterol. The new drug is different from the two antibodies in that it uses a small-interfering RNA to target PCSK9. It’s also given twice a year after two lead-in doses, whereas the two FDA-approved drugs are given every two weeks or once a month.

In the U.S., MedCo—now Novartis—submitted the new drug application for inclisiran to the FDA in December 2019.

4. Drug: Evrenzo (roxadustat)

Companies: FibroGen, AstraZeneca and Astellas

Used for: anemia associated with kidney disease

Est. 2024 sales: $1.488 billion

AstraZeneca, sharing rights with FibroGen has rights to anemia drug Evrenzo (roxadustat) in the U.S. and China, the latter of which has already approved and covered it in both nondialysis-dependent and dialysis-dependent chronic kidney disease patients with anemia. In Japan, its partner Astellas has nabbed a green light for dialysis patients. In the U.S., FibroGen filed for approval in both indications in December 2019.

Roxadustat is the first in the hypoxia-inducible factor prolyl hydroxylase inhibitor class to be approved anywhere. Different from Amgen and Johnson & Johnson’s standard-of-care injection Epogen/Procrit, oral roxa corrects anemia by mimicking a response to reduced oxygen levels.

Roxa could face some in-class competitions soon. These include GlaxoSmithKline’s daprodustat, filed for approval in Japan under a collaboration with Kyowa Kirin. And Akebia Therapeutics and local partner Mitsubishi filed their rival, vadadustat, in Japan in July 2019. In the U.S., Akebia has teamed up with Japanese pharma Otsuka on the anemia treatment.

5. Drug: sacituzumab govitecan

Company: Immunomedics

Used for: triple-negative breast cancer

Est. 2024 sales: $1.44 billion

Triple-negative breast cancer (TNBC) therapy sacituzumab govitecan, as a third-line treatment for late-stage, metastatic TNBC, didn't exactly sail through the FDA: A complete response letter (CRL) in early 2019 nearly sank its approval hopes. But Immunomedics has resubmitted its application for the drug in early December, and the FDA has a decision date set for June.

Sacituzumab govitecan is an antibody drug conjugate including the active ingredient in chemotherapy Onivyde. The chemotherapeutic treatment will be tasked with stacking up against Roche I-O therapy Tecentriq, which was approved to treat TNBC in March.

Cantor analyst Varun Kumar, Ph.D. posited that sacituzumab could be a strong candidate for an acquisition if it nabs an FDA approval as a third-line-or-later treatment. Kumar put the drug's possible acquisition value at $7.1 billion.

6. Drug: filgotinib

Company: Gilead Sciences

Used for: rheumatoid arthritis

Est. 2024 sales: $1.28 billion

With an FDA filing now under speedy review, rheumatoid arthritis candidate filgotinib could go a long way to helping Gilead Sciences push into the anti-inflammatory market.

Filgotinib has already been filed for approval in Europe and Japan, but the U.S. market is where the big bucks will come from, making this an important milestone for Gilead. Recent data readouts shows the medication is better than methotrexate alone while suggesting it has an edge over AbbVie’s Humira, the aging blockbuster rheumatoid arthritis incumbent.

The safety of filgotinib is a particular source of ongoing uncertainty. Gilead and Galapagos think filgotinib is free from some of the safety problems that blighted Pfizer's Xeljanz and Eli Lilly's Olumiant, along with other members of the JAK family. However, AbbVie’s Rinvoq, which, like filgotinib, is specific to JAK1, received a black box warning when it won FDA approval earlier this year.

7. Drug: Palforzia (AR101)

Company: Aimmune

Used for: peanut allergy

Est. 2024 sales: $1.28 billion

On Friday, Jan. 31, the FDA approved Aimmune's Palforzia as a treatment for peanut allergy reactions, including anaphylaxis. Palforzia would set a major precedent in a food allergy field where avoidance is the norm. Despite skepticism from some market watchers, the FDA's approval could put Palforzia on the path to blockbuster status in the next few years.

Palforzia, as a peanut allergy immunotherapy, works by desensitizing patients through gradual doses of peanut protein.

"We believe there are more investor questions on the commercial opportunity for the product given the need for frequent office visits and GI side effects during the up-dosing period," Credit Suisse analyst Vamil Divan, M.D. wrote. "However, we see significant interest in the product from physicians and patients/parents, a side effect profile that appears manageable and a commercial opportunity that can be addressed through a targeted sales force."

8. Drug: valoctocogene roxaparvovec

Company: BioMarin Pharmaceutical

Used for: hemophilia A

Est. 2024 sales: $1.212 billion

BioMarin Pharmaceutical submitted the application for its rival hemophilia A gene therapy, valoctocogene roxaparvovec (valrox), to the FDA at the end of 2019, just as the EMA accepted its package for accelerated review. Meanwhile, its competitor Roche/Spark is still in a lead-in study that tests traditional factor VIII replacement therapy for a future SPK-8011 phase 3.

In preparation for a possible 2020 launch of valrox, BioMarin has upgraded its gene therapy production capacity to 10,000 doses per year, means the company can treat the entire existing severe hemophilia A U.S. patient population in two years—not that it will—ahead of a potential approval for SPK-8011.

Once approved, valrox will first compete for noninhibitor patients against Roche’s antibody drug Hemlibra, which has been rapidly stealing share from factor VIII treatments and contributed CHF 921 million ($950 million) to Roche’s top line in the first 9 months of 2019, because a recent Citi survey of 60 U.S. hematologists showed that they expect to switch 29% of Hemlibra patients and 34% of factor VIII patients over to gene therapy within a year.

9. Drug: rimegepant

Company: Biohaven Pharmaceutical

Used for: migraine

Est. 2024 sales: $897 million

Although Biohaven has already lost the first-to-market oral CGRP race to Allergan, which nabbed an FDA nod for Ubrelvy (ubrogepant) at the end of 2019, industry watchers figured rimegepant represents a more successful sales opportunity, which may be based on the fact that while acute treatment could be rimegepant’s first indication, Biohaven is also looking to expand into the larger prevention market.

Three marketed CGRP drugs—Amgen and Novartis’ Aimovig, Teva’s Ajovy and Eli Lilly’s Emgality—are injections approved to prevent migraine, while Biohaven is aiming to bring an oral option to the table. There’s also Lilly’s newly launched oral drug Reyvow, the first in the serotonin (5-HT)1F receptor agonist class. But the therapy’s side effects, including dizziness and drowsiness, could limit its sales performance to under $500 million at peak.

Biohaven, with oral CGRP migraine drug rimegepant as its first commercial product, has confidence to challenge all those Big Pharma players.

10. Drug: risdiplam

Company: Roche

Used for: spinal muscular atrophy

Est. 2024 sales: $803 million

Roche's risdiplam will follow Novartis' Zolgensma and Biogen's Spinraza into the spinal muscular atrophy market, if the FDA gives it the green light by its May decision deadline.

Risdiplam, a survival motor neuron 2 splicing modifier, is an orally administered liquid that patients would take at home. Biogen's Spinraza is an injection with several loading doses over the first two-and-a-half months and maintenance doses every four months thereafter. Novartis’ gene therapy Zolgensma is a one-time treatment for patients under 2.

If the oral drug reaches approval, Cantor analyst Alethia Young said in a recent note that it could be a "game changer" in SMA.




2021年度专利复审无效十大案件 专利复审和无效审理是对专利权利的保护范围大小甚至权利的有无进行再次认定的程序,决定着专利权的保护基础,一直备受社会关注。4月26日,2021年度专利复审无效十大案件在国家知识产权局开放日活动中正式发布。 案例1.“新颖的磺酰胺类化合物及其作为内皮素受体拮抗剂的应用”发明专利无效案(专利号:ZL01820481.3) 案情简介:专利权人:埃科特莱茵药品有限公司,无效宣告请求人:南京正大天睛制药有限公司。本案涉及的药品马昔腾坦,是首个获批用于治疗肺动脉高压的口服制剂。本案系仿制药申请人在提交仿制药申请后,针对原研药发起的专利挑战。案件审理过程中涉及化学医药领域的多个法律问题,包括权利要求中技术术语的理解、马库什权利要求的性质、马库什化合物和具体化合物优先权的认定、表格化合物充分公开的判断、补充实验数据以及化合物创造性的判断等。 审理结论:在修改的基础上维持有效。 典型意义:本案是药物化合物审理的典型案例,对于优先权的认定、表格化合物充分公开的判断以及化合物创造性的判断具有示范作用。 案例2.“被取代的多环性氨基甲酰基吡啶酮衍生物的前药”发明专利无效案(专利号:ZL201180056716.8) 案情简介:专利权人:盐野义制药株式会社,无效宣告请求人:刘奕彤。本案涉及的玛巴洛沙韦是目前获批的首个、也是唯一一个单剂量口服抗流感药物。案件审理过程中涉及马库什权利要求能否获得说明书的支持,如何准确评价说明书对技术效果的公开以及结构类似的化合物的创造性判断等法律问题。 审理结论:维持有效 典型意义:本案对于准确评价说明书描述的技术效果以及马库什权利要求能否得到说明书支持具有借鉴意义;还阐述了对于“结构类似但用途不同的化合物”,在创造性评判时应当对现有技术提供的机理研究成果进行全面考察,如果其与涉案专利的作用机制缺乏内在联系,则不能从中获得对化合物结构改进以实现不同用途的技术启示。 案例3.“通过图像采集获取网络连接的数据传输方式及其系统”的发明专利无效案(专利号:ZL201010523284.4) 案情简介:专利权人为上海科斗电子科技有限公司,无效宣告请求人为掌阅科技股份有限公司。在本案的无效宣告程序中,双方均提交了大量证据,案件复杂度高,口头审理后,请求人提出了撤案声明。本案审理的重点在于当请求人提出了撤案请求时,审理程序是否终止,即对专利法实施细则第七十二条第2款规定的理解和适用。 审理结论:宣告无效 典型意义:本案对于当事人撤回其请求但审理程序可以不终止的法律规定进行诠释,合理平衡专利权人与社会公众的利益。 案例4.“左心耳封堵器”的发明专利无效案(专利号:ZL201310567987.0) 案情简介:专利权人:先健科技(深圳)有限公司,无效宣告请求人:蔡景莉。本案请求人对专利权人的多个专利权提起了无效宣告请求,本案是其中一件。本案审理中,请求人主张涉案专利缺乏新颖性和创造性,并提交相关现有技术证据。专利权人则主张请求人提出的主要证据属于在申请日以前六个月内“他人未经申请人同意而泄露其内容的”情形,因而涉案专利应享有“新颖性宽限期”,请求人提交的证据不能破坏其新颖性和创造性。 审理结论:宣告无效 典型意义:本案对于“新颖性宽限期”的适用进行诠释,充分论述了对“他人未经申请人同意而泄露其内容”能否享受现有技术豁免的认定思路,明确对于他人未经同意而泄露发明创造内容的情形,如果证据能够表明专利权人在已经知晓情况后两个月内仍未提出声明和提交证明文件,则不能享有新颖性的宽限期。决定强调,专利权人在知晓他人未经同意而泄露技术内容时,应及时履行必要的声明义务。 案例5.“轴流风轮”的发明专利无效案(专利号:ZL200710026747.4) 案情简介:专利权人:广东美的制冷设备有限公司,无效宣告请求人:珠海格力电器股份有限公司。美的、格力、奥克斯是国内空调行业的三大竞争巨头,他们之间的专利纷争不断,本案为格力对美的提出的第二次无效宣告请求,案件所涉及的用于空调外机上的轴流风轮对空调效能具有重要影响,是三家企业专利大战的关键专利之一。 审理结论:宣告无效 典型意义:本案涉及单方委托鉴定报告证据效力的认定,同时,对采用参数定义的产品权利要求与使用公开证据的技术比对提供了审理思路。   案例6.“图像传感器CS3825C”的集成电路布图设计专有权撤销案(登记号:BS.175539928) 案情简介:专利权人:珠海市矽旺半导体有限公司,撤销意见提出人:深圳市芯智锐光电科技有限公司。本案审理涉及多个撤销条款,包括有关保护客体的条例第二条,有关独创性的条例第四条,有关申请登记期限的条例第七条。 审理结论:维持有效 典型意义:本案诠释了专有权保护对象、独创性审理范围以及申请登记期限的判断规则,对布图设计案件的审理具有借鉴意义。 案例7.“仪表机壳”的外观设计专利无效案(专利号:ZL201030122941.5) 案情简介:专利权人:福建顺昌虹润精密仪器有限公司,无效宣告请求人:厦门希科自动化科技有限公司。本案审理过程中涉及多个争议焦点,包括“中间产品”是否属于外观设计保护的客体、判断主体的确定,以及外观设计的对比判断规则。 审理结论:宣告无效 典型意义:本案阐明了作为判断主体的“一般消费者”应当具有的知识水平和认知能力,分析了各设计特征对于整体视觉效果的不同影响权重。 案例8.“防爆装置”的实用新型专利无效案(专利号:ZL201521112402.7) 案情简介:专利权人:宁德时代新能源科技股份有限公司,无效宣告请求人:江苏塔菲尔新能源科技股份有限公司、东莞塔菲尔新能源科技有限公司。本案审理过程中主要争议焦点在于两个方面,一是对技术方案的理解,二是作为技术改进点的多个结构特征对创造性判断的影响。 审理结论:在修改的基础上维持有效。 典型意义:本案是新能源领域结构类产品创造性判断的典型案例,决定强调,判断是否存在技术启示时,应对区别特征之间的关系予以关注,在准确认定涉案专利实际要解决的技术问题和能够达到的技术效果的基础上,客观判断现有技术是否给出了相应的技术启示。 案例9.“用于治疗潜伏性结核的喹啉衍生物” “取代的喹啉衍生物在治疗耐药性分枝杆菌性疾病中的用途”的发明专利无效案(专利号:ZL201210507318.X、ZL200580017016.2) 案情简介:专利权人:詹森药业有限公司,无效宣告请求人:王立群。本系列案涉及两项专利权,该两项专利涉及全球45年来首个抗结核药物“贝达喹啉”。本系列案审理过程中涉及多个争议焦点,包括对权利要求特定技术术语的理解、如何考量说明书实验数据,以及对医药用途发明改进动机与合理成功预期的判断等。 审理结论:在修改的基础上维持有效。 典型意义:本案明确了在医药用途发明的创造性判断中,应当准确评价是否存在“合理的成功预期”。 案例10.“一种用于给排水的活接接头”的实用新型专利无效案(专利号:ZL201920390483.9) 案情简介:专利权人:浙江天雁控股有限公司,无效宣告请求人:孟祥麟。本案审理过程中涉及举证责任、对电子证据真实性的确定、使用公开证据链的认定,以及实用性的判断等诸多法律问题。 审理结论:维持有效。 典型意义:本案明晰了在核实证据优先权时,本国优先权文件的举证责任分配和获取途径。同时,本案还诠释了对实用性意义上“能够产生积极效果”的理解,以及对微信聊天记录、展会等不同类型证据真实性和证明力的认定规则。      

The 2021 patent index targets current patent statistics and trends in Europe

The EPO acts as executive body for the European Patent Organization, an intergovernmental organization that was set up on 7 October 1977 on the basis of the European Patent Convention, to “strengthen co-operation between the States of Europe in respect of the protection of inventions” and establish a single procedure for the grant of patents abiding by certain standard rules.

Chile is the first country to pass neurorights law

On October 25th, 2021, the Senate of the Republic of Chile unanimously approved a bill to amend the constitution to protect brain rights or “neurorights”. Chile became the first nation to have a constitution in force that explicitly addresses the challenges of emerging neurotechnologies. 





备案号:苏ICP备xxxxxx号-1    网站建设:中企动力 南京